Arrythmia, Cardiovascular Diseases, Pacemaker, Physical Activity
Conditions
Brief summary
The benefits of regular physical activity are well-established. Furthermore, the investigators have previously shown that in a population of patients with implanted pacemakers, those who exercise more than 2 hours daily have improved survival compared with those who exercise less than 2 hours daily. In this study, the aim f the investigators is to determine whether the offering subjects with pacemakers who have low levels of physical activity at baseline counseling to increase physical activity levels is effective as measured by their implanted device as well as by an external pacemaker. The investigators seek to enroll about 30 patients into a 6-month 1:1 randomized interventional trial comparing the levels of physical activity in 2 groups, those who receive physical activity counseling versus usual care. The activity levels will be measured with external pedometers and with accelerometers embedded within the pacemaker device.
Detailed description
The benefits of habitual physical activity (PA, activities of at least moderate intensity defined as ≥ 3 metabolic equivalents (METs)) are well-recognized. Emerging information from large data sets strongly suggest high levels of sedentary behavior, defined as activities \<1.5 METs (equivalent to the amount of energy expended during seated activities such as computer work) increases the risk of diabetes, cardiovascular disease, and death, independent of the amount and intensity PA. The increased risk of sedentary behavior appears to be mediated at least in part by reduced insulin sensitivity, impaired lipid metabolism, increased vascular inflammation, and increased thrombotic tendencies. The internal accelerometer embedded in Medtronic pacemakers registers, stores, and reports total number of active time based on a threshold activity intensity level of approximately 70 steps/min (estimated to be \> 1.5 METs). This implanted accelerometer, combined with the regular follow-up required for appropriate care make individuals who have undergone Medtronic pacemaker implantation an ideal population in which to evaluate the impact of altering sedentary behavior on mortality and cardiovascular events. The hypotheses are as follows: 1. a 12 week intervention to increase moderate intensity physical activity delivered at the point of care in patients with pacemakers will result in parallel increases in active time as measured by the pacemaker and step count as measured by pedometer. 2. the increase in activity measured by both the metrics in hypothesis 1 will be greater than with usual care. Potential subjects who are interested in the study will have a screening visit to determine whether they meet the inclusion and exclusion criteria. Those who qualify and agree to participate will be randomized into either the Physical Activity Counseling arm (intervention arm) or the Patient Usual Care arm (control arm). Subjects in the interventional arm will be given a pedometer and physical activity counseling on a regular basis for 3 months. Physical activity data from their external pedometer will be collected every 2 weeks via phone calls. Accelerometry data from the implanted pacemaker will be collected from the subject's medical record as pacemaker interrogations are performed every 3 months as part of routine clinical care. After the initial 3 month interventional phase is complete, these subjects will be followed for another 3 months with collection of pedometer as well as accelerometer data as described above. Subjects in the control arm will be given pedometers for the week prior to pacemaker interrogation. These subjects will be called to report the number of steps they walked each day prior to the interrogation. Their accelerometry data will be captured through routine clinical pacemaker interrogations. The primary outcome is the physical activity level in each group as measured by the accelerometer at time 0, 3 months and 6 months. The secondary outcome is the step count in each group as measured by the pedometer at the same time points.
Interventions
Subjects in this arm will receive counseling on how to increase their physical activity level.
Subjects will undergo their usual care without intervention
Sponsors
Study design
Eligibility
Inclusion criteria
* Age \> 55 years old * Clinical indication for placement of permanent pacemaker * LVEF of ≥ 50% at the time of or within 72 hours of implantation. * Able to ambulate * Average active time of ≤ 2 hours/day based on Revo or EnRhythm Accelerometery read out for the 3 month period prior to enrollment * Able to take 650 steps over 10 minutes following pacemaker implantation (\ 2-2.5 mph walking speed)
Exclusion criteria
* Follow up for implantation planned at a non-study center at the time of implantation. * Individuals with and expected life span of 1 year or less at the time of implantation * Known history of cognitive impairment or inability to follow study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Physical Activity Level as Measured by Embedded Accelerometer | 6 months | This is the daily measured active hours in the device |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physical Activity Level as Measured by External Pedometer | 6 months | this is a daily step count (one week average) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Physical Activity Counseling Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
Physical activity counseling: Subjects in this arm will receive counseling on how to increase their physical activity level. | 7 |
| Patient Usual Care Subjects will undergo usual care without intervention in this study arm
Usual care: Subjects will undergo their usual care without intervention | 6 |
| Total | 13 |
Baseline characteristics
| Characteristic | Physical Activity Counseling | Total | Patient Usual Care |
|---|---|---|---|
| ACEI or ARB Therapy | 3 Participants | 7 Participants | 4 Participants |
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 7 Participants | 13 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 84 years STANDARD_DEVIATION 5 | 80 years STANDARD_DEVIATION 6 | 75 years STANDARD_DEVIATION 5 |
| Atrial Fibrillation | 3 Participants | 7 Participants | 4 Participants |
| Beta Blocker Therapy | 4 Participants | 7 Participants | 3 Participants |
| Body Mass Index | 30.0 kg/m2 STANDARD_DEVIATION 5 | 31.2 kg/m2 STANDARD_DEVIATION 5.7 | 32.5 kg/m2 STANDARD_DEVIATION 6.6 |
| Calculated Gait Speed | 0.84 m/sec STANDARD_DEVIATION 0.14 | 0.85 m/sec STANDARD_DEVIATION 0.16 | 0.86 m/sec STANDARD_DEVIATION 0.18 |
| Coronary Stent | 1 Participants | 1 Participants | 0 Participants |
| Creatinine Clearance < 60 mL/min/1.73 m2 | 4 Participants | 5 Participants | 1 Participants |
| Current Smoker | 0 Participants | 1 Participants | 1 Participants |
| DBP | 70 mmHg STANDARD_DEVIATION 9 | 73 mmHg STANDARD_DEVIATION 14 | 77 mmHg STANDARD_DEVIATION 18 |
| Diabetes | 0 Participants | 3 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 13 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Heart Failure | 0 Participants | 2 Participants | 2 Participants |
| High Degree AV Block | 6 Participants | 9 Participants | 3 Participants |
| History of Non-Sustained Ventricular Tachycardia | 2 Participants | 7 Participants | 5 Participants |
| History of Sustained Ventricular Tachycardia | 0 Participants | 3 Participants | 3 Participants |
| HMG CoA Reductase Therapy | 4 Participants | 8 Participants | 4 Participants |
| HR | 66 bpm STANDARD_DEVIATION 4 | 68 bpm STANDARD_DEVIATION 6 | 70 bpm STANDARD_DEVIATION 7 |
| Hyperlipidemia | 6 Participants | 12 Participants | 6 Participants |
| Hypertension | 6 Participants | 10 Participants | 4 Participants |
| LVEF% | 62 % STANDARD_DEVIATION 3 | 60 % STANDARD_DEVIATION 4 | 57 % STANDARD_DEVIATION 4 |
| LV End Diastolic Dimension | 43 mm STANDARD_DEVIATION 3 | 44 mm STANDARD_DEVIATION 5 | 44 mm STANDARD_DEVIATION 6 |
| LV End Systolic Dimension | 26 mm STANDARD_DEVIATION 2 | 28 mm STANDARD_DEVIATION 6 | 30 mm STANDARD_DEVIATION 9 |
| Moderate or Greater Mitral Regurgitation | 2 Participants | 2 Participants | 0 Participants |
| Pacemaker detected active minutes | 1.59 hours/day STANDARD_DEVIATION 0.44 | 1.60 hours/day STANDARD_DEVIATION 0.33 | 1.62 hours/day STANDARD_DEVIATION 0.18 |
| Pedometer-Based Daily Step Count | 2827 steps/day STANDARD_DEVIATION 1641 | 2618 steps/day STANDARD_DEVIATION 1594 | 2474 steps/day STANDARD_DEVIATION 1623 |
| Percent Atrial Pacing | 66 % STANDARD_DEVIATION 31 | 61 % STANDARD_DEVIATION 34 | 53 % STANDARD_DEVIATION 38 |
| Percent Ventricular Pacing | 12 % STANDARD_DEVIATION 21 | 22 % STANDARD_DEVIATION 38 | 34 % STANDARD_DEVIATION 51 |
| Prior CABG | 1 Participants | 1 Participants | 0 Participants |
| Prior CVA | 1 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 6 Participants | 11 Participants | 5 Participants |
| Region of Enrollment United States | 7 participants | 13 participants | 6 participants |
| SBP | 131 mmHg STANDARD_DEVIATION 27 | 126 mmHg STANDARD_DEVIATION 22 | 121 mmHg STANDARD_DEVIATION 14 |
| Sex: Female, Male Female | 6 Participants | 11 Participants | 5 Participants |
| Sex: Female, Male Male | 1 Participants | 2 Participants | 1 Participants |
| Sick Sinus Syndrome | 1 Participants | 4 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 6 |
| other Total, other adverse events | 0 / 7 | 0 / 6 |
| serious Total, serious adverse events | 0 / 7 | 0 / 6 |
Outcome results
Physical Activity Level as Measured by Embedded Accelerometer
This is the daily measured active hours in the device
Time frame: 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Physical Activity Counseling | Physical Activity Level as Measured by Embedded Accelerometer | 1.97 active hours/day | Standard Deviation 0.56 |
| Patient Usual Care | Physical Activity Level as Measured by Embedded Accelerometer | 1.77 active hours/day | Standard Deviation 0.22 |
Physical Activity Level as Measured by External Pedometer
this is a daily step count (one week average)
Time frame: 6 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Physical Activity Counseling | Physical Activity Level as Measured by External Pedometer | 1769 steps/day | Standard Deviation 771 |
| Patient Usual Care | Physical Activity Level as Measured by External Pedometer | 2487 steps/day | Standard Deviation 1800 |